Global(EN)
Statement
Statement
We have recently noticed that some companies and individuals illegally forged and used authorization documents from Sinovac Biotech Co., Ltd. (“Sinovac Beijing”) or Sinovac Life Sciences Co., Ltd. (“Sinovac Life Sciences”), two subsidiaries of Sinovac Biotech Ltd. (“Sinovac”), to hold out that Sinovac Beijing or Sinovac Life Sciences has authorized them to act as the distributor to distribute the Covid-19 vaccine CoronaVac® and the other vaccine products in the markets outside China.
We wish to clarify that:
(i) the Covid-19 vaccine CoronaVac® is developed, manufactured and distributed by Sinovac Life Sciences;
(ii) Sinovac Beijing is not engaged in distribution of the Covid-19 vaccine CoronaVac® outside China; and
(ii) neither Sinovac nor any of its subsidiaries has ever signed any authorization letter or similar documents for any company or individual within China to authorize them to distribute the Covid-19 vaccine CoronaVac® outside China.
We hereby reiterate that, without signing written contracts with us, no entity or individual may hold out that it is or is authorized to be engaged in sale, distribution or other marketing or promotion activities related to any of Sinovac’s vaccine products.
Concerning the illegal activities of document forging and fraudulence as mentioned, we reserve all the rights to take actions, including legal actions, to seek remedies and pursue liabilities.
Sinovac Biotech Ltd.
28 January 2021
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.
SINOVAC's COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, a hepatitis A vaccine manufactured by the Company, passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine, that was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) was prequalified by WHO.
SINOVAC was the first company that granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC has been continually dedicating itself to new vaccine research and development, with more combination vaccine products in the pipeline, and constantly exploring opportunities in the international market. SINOVAC looks forward to conducting more extensive and in-depth trade and cooperation with more countries, enterprises, and professional institutions.
For more information, please see the Company’s website at www.sinovac.com.
Contacts
Sinovac Biotech Ltd.
Helen Yang
+86-10-8279-9871 or
+86-10-5693-1897
Fax: +86-10-6296-6910
ir@sinovac.com
ICR Inc.
Bill Zima
U.S.: 1-646-308-1707
william.zima@icrinc.com
